Industry Insights: Where Does Immuno-Oncology Fit in a Value-Based Care Delivery Model?

February 2016

For Specialty Physicians:

VitalSource™ GPO
Multi-Specialty Solutions
Oncology Solutions
Urology Solutions

For Specialty Manufacturers:

Business Solutions
Logistical Solutions
Patient Solutions

Bruce Feinberg, DO

Vice President
Chief Medical Officer 
Cardinal Health Specialty Solutions

The American Society of Clinical Oncology (ASCO) has named cancer immunotherapy the “Advance of the Year” for 2016.

In an article published in The American Journal of Managed Care’s Evidence Based Oncology, Cardinal Health Specialty Solutions CMO and VP of Clinical Affairs, Dr. Bruce Feinberg investigates recent advances in immunotherapy and how it fits within a value-based care delivery model.

While these advances have expanded our understanding of immunotherapy, they also have added more complexity to its value assessment, which will be a critical factor in stakeholder adoption. Balancing efficacy, toxicity, and value is an undertaking for which traditional clinical research seems ill-designed, and will require the rapid expansion of health economics and outcomes research into this nascent field.

Real-world Insights

Make informed decisions with evidence-based HEOR studies in oncology, rheumatology and other specialty therapeutic areas.

Members Login

Sign in to the members-only section of VitalSource™ GPO

Your portal to valuable resources designed to help maximize profitability and optimize efficiency.

Become a member today

VitalSource™ GPO is a consultative partner who delivers meaningful solutions to make your business more successful.

Join now